Envoy Medical, Inc. (NASDAQ: COCH), headquartered in White Bear Lake, Minnesota, is a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Envoy Medical’s technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire.
Company profile
Ticker
COCH
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
Anzu Special Acquisition Corp I
SEC CIK
Corporate docs
IRS number
861369123
COCH stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
12 Apr 24
S-1/A
IPO registration (amended)
5 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Envoy Medical Secures Up To $10 Million Term Debt Financing to Advance Upcoming Clinical Trial
4 Mar 24
S-1/A
IPO registration (amended)
14 Feb 24
S-1
IPO registration
18 Jan 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
19 Dec 23
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.84 mm | 16.84 mm | 16.84 mm | 16.84 mm | 16.84 mm | 16.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.13 mm | 670.32 k | 1.03 mm | 181.47 k |
Cash used (since last report) | n/a | n/a | 7.73 mm | 4.59 mm | 7.05 mm | 1.24 mm |
Cash remaining | n/a | n/a | 9.11 mm | 12.25 mm | 9.79 mm | 15.60 mm |
Runway (months of cash) | n/a | n/a | 8.1 | 18.3 | 9.5 | 85.9 |
Institutional ownership, Q3 2023
29.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 3 |
Closed positions | 20 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 788.53 mm |
Total shares | 5.80 mm |
Total puts | 0.00 |
Total calls | 1.76 mm |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Aristeia Capital | 1.09 mm | $89.75 mm |
NMR Nomura | 633.33 k | $50.35 mm |
Periscope Capital | 312.59 k | $27.82 mm |
BNP Paribas Arbitrage | 283.33 k | $24.08 mm |
Bracebridge Capital | 262.16 k | $23.33 mm |
Shaolin Capital Management | 208.58 k | $19.00 k |
Jane Street | 208.19 k | $18.53 mm |
Whitebox Advisors | 184.00 k | $16.38 mm |
Sculptor Capital | 182.14 k | $15.00 mm |
Moore Capital Management | 166.67 k | $14.17 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Feb 24 | Glen A Taylor | Warrant Class A Common Stock | Buy | Acquire P | Yes | No | 1.24 | 500,000 | 620.00 k | 500,000 |
21 Nov 23 | Brent T. Lucas | Class A Common Stock | Buy | Acquire P | No | No | 0.92 | 2,380 | 2.19 k | 120,831 |
21 Nov 23 | Brent T. Lucas | Class A Common Stock | Buy | Acquire P | No | No | 0.98 | 10,000 | 9.80 k | 118,451 |
20 Nov 23 | Glen A Taylor | Series A Preferred Stock Class A Common Stock | Buy | Acquire P | Yes | No | 10 | 100,000 | 1.00 mm | 1,100,000 |
20 Nov 23 | Glen A Taylor | Series A Preferred Stock Class A Common Stock | Other | Dispose J | Yes | No | 10 | 100,000 | 1.00 mm | 1,000,000 |
15 Oct 23 | Janis Smith-Gomez | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 2.4 | 25,000 | 60.00 k | 25,000 |
News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 Apr 24
Lake Street Maintains Buy on Envoy Medical, Raises Price Target to $6
3 Apr 24
Press releases
Envoy Medical to Present at the Planet MicroCap Showcase: Vegas 2024
24 Apr 24
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation – COCH
22 Apr 24
ROSEN, A LONGSTANDING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH
20 Apr 24
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation – COCH
18 Apr 24
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation – COCH
15 Apr 24